Thymic Carcinoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (28 November 2021) | Viewed by 12104
Special Issue Editor
Interests: thymic cancer; surgery; chemotherapy; radiotherapy; PET; pathology; prognostic factor
Special Issue Information
Dear Colleagues,
Thymic epithelial tumors, which are generally classified as thymomas and thymic carcinomas, are uncommon neoplasms presenting in less than 2.0% of all malignancies. In particular, thymic carcinoma is a rare neoplasm with a dismal outcome and no available therapeutic agents for its advanced form. Therefore, the identification of new targets that can serve as predictive and prognostic markers for the development of an optimal treatment plan is essential. To treat thymic cancer, surgery, radiotherapy and chemotherapy are chosen according to its expansion. Surgical resection is absolutely suitable for early disease, but it is hard to cure the patients with advanced disease by systemic chemotherapy or radiotherapy. Meanwhile, it is of critical importance to develop predictive biomarkers (e.g., PET as an indicator of metabolic activity) and different kinds of pathologic markers. Molecular imaging techniques have been under recent development in oncology. An optimal approach realizes the improvement of curative treatment of thymic carcinoma. The scope of this Special Issue includes the therapeutic significance of new modalities, molecular imaging and optimal biomarkers.
Prof. Dr. Kyoichi Kaira
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- thymic cancer
- surgery
- chemotherapy
- radiotherapy
- PET
- pathology
- prognostic factor
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.